ANGLE plc’s Microfluidic Liquid Biopsy Technology Featured in Research Presented at American Association of Cancer Research...
April 03 2017 - 7:30AM
Business Wire
Poster presentations at AACR demonstrate
isolation of circulating tumor cells in blood using the Parsortix™
system, enabling subsequent molecular characterization
ANGLE plc (AIM:AGL OTCQX:ANPCY), a UK-based medical diagnostics
company with pioneering products for cancer diagnostics and fetal
health, announces three poster presentations that highlight the
advantages of marker-independent capture of circulating tumor cells
(CTCs) using the Parsortix cell separation system in blood samples
from patients with various types of cancer. The posters will be
presented at the American Association of Cancer Researchers Annual
Meeting April 1-5.
Researchers Martha Zavridou, Evi Lianidou and colleagues from
University of Athens and Attikon University Hospital, (Athens
Greece) successfully used the Parsortix system for the first time
to isolate CTCs from patients with head and neck squamous cell
carcinoma. They were able to extract RNA of excellent quality from
the CTCs, which was then used for RT-qPCR gene expression analysis.
Preliminary results showing over-expression of key genes -- such as
PD-L1 in >26% of samples -- could have significant clinical
value in identifying biomarker-positive patients who are likely to
respond to individualized immunotherapy.
Yvonne Maertens and a team of researchers from University
Hospital Muenster (Germany) compared the ability to isolate and
detect circulating renal cancer cells from patient blood samples
using the size-based Parsortix system, EpCAM-based CTC enrichment,
or methods based on cell density or invasive capacity. The
Parsortix system yielded the highest recovery rates of CTCs.
The Parsortix system was used by researchers Jenny Antonello et
al. from CRUK Manchester and the Christie NHS Foundation Trust
Manchester (U.K.), together with an epitope-dependent EpCAM-based
enrichment method to capture CTCs over time from blood samples of
patients with prostate cancer as part of a study to identify and
monitor biomarkers that may be linked, either alone or in
combination, to clinical status or outcomes.
“We are very pleased with the increased adoption and utilization
of Parsortix™ cell separation in such diversified research. We
continue to see greater utilization of our flagship technology in
key liquid biopsy research,” said ANGLE Founder and Chief
Executive, Andrew Newland.
About ANGLE plc
ANGLE is a UK-based specialist medtech company commercializing
the Parsortix system, a cell separation technology that enables a
simple blood test to harvest targeted cells for investigation, such
as circulating tumor cells (CTCs) for molecular profiling and
analysis. Parsortix can help deliver targeted cancer diagnostics
that has the potential to inform personalized treatment of cancer.
It is also designed to be compatible with existing major medtech
analytical platforms and to act as a companion diagnostic for major
pharma in helping to identify patients that will benefit from a
particular drug and then monitoring the drug’s effectiveness. ANGLE
has established formal collaborations with world-class cancer
centers and is working with these cancer centers to demonstrate key
applications for its Parsortix non-invasive cancer diagnostic
system as a liquid biopsy. In addition to cancer cells, the
Parsortix technology has the potential for deployment for other
clinically significant cell types in the future.
ANGLE is a public company trading on the AIM market of the
London Stock Exchange under the ticker symbol AGL and on the OTCQX
market in the US under the ticker symbol ANPCY. For more
information, www.angleplc.com.
All of the research outcomes described in this communication are
for research purposes only and not for use in diagnostic
procedures.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170403005248/en/
ANGLE plcPeggy Robinson, 914-525-5928Vice PresidentorMedia
ContactBrandwidth Solutions LLCDebra Harrsch,
267-577-0806dharrsch@brandwidthsolutions.com
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024